Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

@article{Hess2006PharmacogenomicPO,
  title={Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.},
  author={K. Hess and K. Anderson and W. Symmans and V. Valero and N. Ibrahim and J. Mejia and D. Booser and R. Theriault and A. Buzdar and P. Dempsey and R. Rouzier and N. Sneige and J. Ross and T. Vidaurre and H. G{\'o}mez and G. Hortobagyi and L. Pusztai},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 26},
  pages={
          4236-44
        }
}
  • K. Hess, K. Anderson, +14 authors L. Pusztai
  • Published 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases. PATIENTS AND METHODS One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed with oligonecleotide microarrays on fine-needle aspiration specimens. We developed predictors of pCR… Expand
A Robust Predictor of Response to Preoperative Chemotherapy for Breast Cancer
TLDR
The rank-based pCR predictor derived from a large cohort of samples can accurately and robustly predict patients with high probability of achieving pCR after chemotherapy. Expand
Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
TLDR
Two conceptually different predictors performed similarly in this validation study and tended to identify the same patients as responders and a genomic predictor that relied solely on a composite of individual drug sensitivity predictions from cell lines did not show any predictive value. Expand
Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
TLDR
The rank-based predictors for response and prognosis can accurately and robustly predict patients with improved prognosis who might benefit from neoadjuvant taxane and anthracycline-based chemotherapy. Expand
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
TLDR
Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. Expand
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
TLDR
Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients, and there was no significant correlation between observed response and predicted response either for individual drug predictors or combined predictions. Expand
Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
TLDR
The 30-gene predictor can identify patients with greater than average sensitivity to T/FAC chemotherapy but it captured molecular equivalents of clinical phenotype, which suggests that the genomic predictor may have regimen specificity. Expand
Prediction model of the response to neoadjuvant chemotherapy in breast cancers by a Naive Bayes algorithm
  • Libo Yang, Bo Fu, +9 authors H. Bu
  • Computer Science, Medicine
  • Comput. Methods Programs Biomed.
  • 2020
TLDR
Instead of whole transcriptome-based technologies, panel gene expression with tens of essential genes implemented in a machine learning model has predictive potential for chemosensitivity in breast cancers. Expand
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
  • C. Liedtke, C. Hatzis, +8 authors L. Pusztai
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
High GGI is associated with increased sensitivity to neoadjuvant paclitaxel plus fluorouracil, adriamycin, and cyclophosphamide chemotherapy in both ER-negative and ER- positive patients, but it remains a predictor of worse survival in ER-positive patients. Expand
Protein profiling predicts the response to anthracycline and taxanes based neo-adjuvant chemotherapy in breast cancer
TLDR
The proteomic predictive model has the potential to predict pathological response to neo-adjuvant TA chemotherapy and to develop a multi-protein predictive model for breast cancer. Expand
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
TLDR
A 10-protein biomarker panel that classifies breast cancer into prognostic groups that may have potential utility in the management of patients who receive anthracycline-taxane-based NST is developed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
  • M. Ayers, W. Symmans, +15 authors L. Pusztai
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The results suggest that transcriptional profiling has the potential to identify a gene expression pattern in breast cancer that may lead to clinically useful predictors of pCR to T/FAC neoadjuvant therapy. Expand
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
  • L. Gianni, M. Zambetti, +14 authors S. Shak
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Quantitative expression of ER-related genes, proliferation genes, and immune- related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel, suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit. Expand
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
TLDR
The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers. Expand
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
TLDR
The data suggest that low tau expression renders microtubules more vulnerable to paclitaxel and makes breast cancer cells hypersensitive to this drug, which may be used as a marker to select patients for pac litaxel therapy. Expand
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
  • B. Fisher, J. Bryant, +13 authors H. Bear
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology. Expand
Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
TLDR
Recent progress in this field is reviewed including experience from the breast cancer pharmacogenomic marker discovery program at the Nellie B. Connally Breast Center of the University of Texas M. D. Anderson Cancer Center. Expand
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
TLDR
Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate. Expand
Outcome signature genes in breast cancer: is there a unique set?
TLDR
It is shown that in fact the resulting set of genes is not unique; it is strongly influenced by the subset of patients used for gene selection, and the correlations fluctuate strongly when measured over different subsets of patients. Expand
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
TLDR
The change in schedule of paclitaxel from once every 3 weeks to a more frequent administration significantly improved the ability to eradicate invasive cancer in the breast and lymph nodes. Expand
Breast cancer biomarkers and molecular medicine
The first part of this two-part review of established and emerging breast cancer biomarkers and molecular diagnostics considers breast cancer predisposition, screening tests for diagnosis, diagnosisExpand
...
1
2
3
4
...